Clofoctol
From Wikipedia, the free encyclopedia
 |
|
|
Clofoctol
|
|
| Systematic (IUPAC) name | |
| 2-[(2,4-dichlorophenyl)methyl]- 4-(2,4,4-trimethylpentan-2-yl)phenol |
|
| Identifiers | |
| CAS number | |
| ATC code | J01 |
| PubChem | |
| Chemical data | |
| Formula | C21H26Cl2O |
| Mol. mass | 365.336 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 98%[1] |
| Metabolism | Hepatic glucuronidation[1] |
| Half life | ? |
| Excretion | Biliary[1] |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Rectal (suppository)[1][2] |
Clofoctol is a bacteriostatic antibiotic. It is used in the treatment of respiratory tract and ear, nose and throat infections caused by Gram-positive bacteria.[1][2]
It is marketed in France under the trade name Octoplus and in Italy as Gramplus.
It is only functional against Gram-positive bacteria.[3]
[edit] References
- ^ a b c d e Gramplus (Italian). Studio Medico Torrino (July 25, 2007). Retrieved on 2007-08-10.
- ^ a b Clofoctol (French). BIAM (July 16, 1999). Retrieved on 2007-08-10.
- ^ Combe J, Simonnet F, Yablonsky F, Simonnet G (1980). "[Clofoctol binding by the bacteria (author's transl)]" (in French). J Pharmacol 11 (4): 411–25. PMID 6782374.
 |
This antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
|
||||||||||||||||||||
